ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,22
-0,82%
Dow Jones
40 211,72
0,00%
DAX
18 485,45
-0,62%
Brent Oil
82,965
-1,63%
Bitcoin
63 857,45
-1,54%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
17/01/200601h22PR Newswire (US)Allos Therapeutics Announces CEO Succession PlansNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/01/200614h00PR Newswire (US)Results Published in Journal of Clinical Oncology Affirm Survival Benefit of EFAPROXYN(TM) in Patients with Brain Metastases OriNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/12/200514h02PR Newswire (US)Retrospective Analysis Finds EFAPROXYN(TM) Extends Survival With Quality of Life in Patients With Brain Metastases Originating FNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/12/200514h00PR Newswire (US)PDX Shows Promising Activity in Patients With Resistant T-Cell LymphomasNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/11/200514h02PR Newswire (US)Allos Therapeutics Appoints Timothy P. Lynch to Board of DirectorsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/11/200514h01PR Newswire (US)Interim Phase 1 Data on RH1 Presented at AACR-NCI-EORTC ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/11/200514h00PR Newswire (US)Data From Phase 1 Clinical Trial of PDX (Pralatrexate) to be Presented at American Society of Hematology Annual MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/11/200514h02PR Newswire (US)Allos Therapeutics Reports Third Quarter 2005 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/11/200514h02PR Newswire (US)Data on EFAPROXYN(TM) and RH1 to be Presented at Upcoming Scientific ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
21/10/200518h02PR Newswire (US)Allos Therapeutics Announces Dismissal of Securities Class Action LawsuitNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/10/200515h01PR Newswire (US)Allos Therapeutics to Present at the 2005 BIO Investor ForumNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/10/200500h06PR Newswire (US)Allos Therapeutics Announces Withdrawal of European Marketing Authorization Application for REVAPROXYN(TM)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
22/09/200515h00PR Newswire (US)Allos Therapeutics to Present at the UBS Global Life Sciences ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/09/200515h02PR Newswire (US)Allos Therapeutics to Present at the Bear Stearns Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/09/200515h00PR Newswire (US)Results Published in Journal of Clinical Oncology Demonstrate Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients ReceiNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/08/200515h01PR Newswire (US)Allos Therapeutics Reports Second Quarter 2005 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/06/200521h28PR Newswire (US)Allos Therapeutics and Hovione Enter Into Manufacturing Agreement for EFAPROXYN(TM) Bulk Drug SubstanceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/05/200500h46PR Newswire (US)Allos Therapeutics Announces Stockholder Approval of Share ExchangeNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/05/200515h00PR Newswire (US)Allos Therapeutics to Present at the Needham & Company Biotechnology ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/05/200515h01PR Newswire (US)Allos Therapeutics Reports First Quarter 2005 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/03/200512h00PR Newswire (US)Allos Therapeutics to Present at SG Cowen's Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/03/200512h02PR Newswire (US)Allos Therapeutics Reports 2004 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/03/200512h00PR Newswire (US)Allos Therapeutics Announces $50 Million FinancingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/01/200514h00PR Newswire (US)Allos Therapeutics Initiates Phase 1 PDX Study in Patients With Non-Small Cell Lung CancerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/01/200514h01PR Newswire (US)Allos Therapeutics Announces Expansion of ENRICH Trial Into EuropeNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/12/200414h00PR Newswire (US)Allos Therapeutics Licenses New Cancer CompoundNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/12/200417h38PR Newswire (US)Allos Therapeutics Investigator Presents Updated Survival Results From Phase III REACH Study at San Antonio Breast Cancer SymposNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/11/200412h00PR Newswire (US)Allos Therapeutics to Present at Credit Suisse First Boston's Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/11/200414h01PR Newswire (US)Allos Therapeutics Announces Presentation on EFAPROXYN(TM) at Chemotherapy Foundation Symposium XXIINASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/11/200422h30PR Newswire (US)Allos Therapeutics Reports Third Quarter 2004 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

NYSE
COF
Capital One Financial
LSE
0A3G
Ishares Core Msci Europe...
LSE
WWH
Worldwide Healthcare
LSE
CBUG
Ish Ust 3-7yr ?
LSE
ATST
Alliance
NYSE
TIER
Tier Reit Inc.
NYSE
AVP
Avon Products
NASDAQ
BRKR
Bruker
USOTC
SRCH
Searchlight Minerals (PK)
FX
USDRUB
US Dollar vs RUB
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés